About Lyra Therapeutics, Inc.
https://lyratherapeutics.comLyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.
CEO
Maria Palasis
Compensation Summary
(Year 2022)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-05-28 | Reverse | 1:50 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:2.83M
Value:$5.35M
POLARIS VENTURE MANAGEMENT CO. V, L.L.C.
Shares:1.1M
Value:$2.08M
PERCEPTIVE ADVISORS LLC
Shares:229.38K
Value:$433.53K
Summary
Showing Top 3 of 30
About Lyra Therapeutics, Inc.
https://lyratherapeutics.comLyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $25K ▼ | $6.18M ▼ | $-5.98M ▲ | -23.94K% ▼ | $-3.38 ▲ | $-5.88M ▲ |
| Q2-2025 | $183K | $8.41M ▼ | $-7.44M ▲ | -4.06K% ▲ | $-5.51 ▼ | $-7.24M ▲ |
| Q1-2025 | $183K ▼ | $9.02M ▼ | $-8.55M ▲ | -4.67K% ▲ | $-0.13 ▲ | $-7.83M ▲ |
| Q4-2024 | $209K ▲ | $11.62M ▼ | $-10.98M ▲ | -5.25K% ▲ | $-0.17 ▲ | $-9.62M ▼ |
| Q3-2024 | $195K | $12.64M | $-11.87M | -6.09K% | $-0.18 | $-9.6M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $22.05M ▼ | $43.71M ▼ | $48.04M ▼ | $-4.33M ▼ |
| Q2-2025 | $29.78M ▼ | $52.57M ▼ | $50.95M ▼ | $1.62M ▼ |
| Q1-2025 | $31.73M ▼ | $56.32M ▼ | $52.44M ▼ | $3.87M ▼ |
| Q4-2024 | $40.58M ▼ | $66.35M ▼ | $54.75M ▼ | $11.59M ▼ |
| Q3-2024 | $51.63M | $78.76M | $58.14M | $20.62M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-5.98M ▲ | $-7.36M ▼ | $0 ▲ | $-368K ▼ | $-7.73M ▼ | $-7.36M ▼ |
| Q2-2025 | $-7.44M ▲ | $-6.59M ▲ | $-2K ▼ | $4.64M ▲ | $-1.95M ▲ | $-6.61M ▲ |
| Q1-2025 | $-8.55M ▲ | $-8.84M ▲ | $0 ▼ | $0 ▲ | $-8.84M ▼ | $-8.84M ▲ |
| Q4-2024 | $-10.98M ▲ | $-11.35M ▲ | $28.13M ▲ | $-1K ▲ | $16.78M ▲ | $-11.29M ▲ |
| Q3-2024 | $-11.87M | $-16.22M | $8.14M | $-23K | $-8.11M | $-16.27M |
CEO
Maria Palasis
Compensation Summary
(Year 2022)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-05-28 | Reverse | 1:50 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:2.83M
Value:$5.35M
POLARIS VENTURE MANAGEMENT CO. V, L.L.C.
Shares:1.1M
Value:$2.08M
PERCEPTIVE ADVISORS LLC
Shares:229.38K
Value:$433.53K
Summary
Showing Top 3 of 30